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Abstract
This focused review presents a critical appraisal of the World Heart Federation criteria for 
the echocardiographic diagnosis of rheumatic heart disease (RHD) and its performance 
in African RHD screening programmes. It identifies various logistical and methodological 
problems that negatively influence the current guideline’s performance. The authors 
explore novel RHD screening methodology that could address some of these shortcomings 
and if proven to be of merit, would require a paradigm shift in the approach to the 
echocardiographic diagnosis of subclinical RHD.
Background
Rheumatic heart disease (RHD) remains one of the 
leading causes of cardiovascular morbidity and mortality 
in developing countries (1). Sub-Saharan Africa has been 
identified as an endemic RHD region with extrapolated 
figures estimating the disease burden of latent RHD to 
be anywhere from 1.1 to 13.2 million (2). To address the 
burden of RHD on the continent, the African Union 
adopted the Addis Ababa Communique (3) at the 25th 
African Union Heads of State and Government Summit 
held in Johannesburg, 2015.
The communique is a seminal position statement 
devised by RHD clinicians and researchers affiliated with 
the Pan-African Society of Cardiology (PASCAR) and 
outlies seven priority areas of action for the eradication 
of RHD in Africa. The fourth recommendation of the 
communique recognises the pivotal role that cardiac 
ultrasound will fulfil to assist in ‘the early detection, 
diagnosis, secondary prevention and treatment of RHD’ (3).
However, an incomplete understanding of the natural 
history of latent RHD, coupled with various deficiencies in 
the current RHD echocardiographic diagnostic guideline, 
has precluded its endorsement for use in large-scale 
echocardiographic screening programmes.
This article will review the 2012 World Heart 
Federation (WHF) echocardiographic criteria for the 
diagnosis of RHD and its performance in African RHD 
screening programmes. It hopes to outline the various 
deficiencies inherent to the current guideline and 
highlight novel alternative methods of echocardiographic 
RHD identification that may improve the performance of 
screening criteria.
The role of echocardiography in 
RHD screening
The efficacy of secondary prevention in acute rheumatic 
fever (ARF) is well documented and originates from 
current understanding that individuals with a previous 
history of ARF are predisposed to recurrent attacks, 
which can be prevented by the administration of 
regular prophylactic antibiotics (4, 5, 6). However, the 
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accurate identification of those with an increased risk 
is fraught with complexities as it is estimated that up 
to 40% of individuals with established RHD have no 
recollection of having symptoms compatible with an 
ARF episode (7).
This provides an ideal opportunity for disease control 
programmes to institute targeted screening to identify those 
individuals at risk for further progression to symptomatic 
disease. Prior to the advent of echocardiography and its 
utility in RHD diagnosis, RHD screening programmes 
relied on cardiac auscultation to identify potential 
cases of RHD. Most of the published prevalence rates 
of antecedent RHD screening programmes in Africa 
ranged from 1.0 to 10.2/1000 (8, 9, 10, 11, 12). However, 
echocardiography has since proven to be a more sensitive 
screening tool with detection rates of RHD considerably 
higher than those of its auscultation-based counterpart 
with prevalence rates in Africa as high as 30.4/1000 (13). 
The prospect of early detection of subclinical disease 
(asymptomatic individuals with no previous history of 
ARF) coupled with the presumed efficacy of secondary 
prophylaxis to avert progression to severe symptomatic 
disease led to a reinvigoration of African RHD research 
(14, 15, 16, 17, 18, 19, 20).
The 2012 World Heart Federation criteria
Due to the systematic differences in the diagnostic 
approach and reporting of screening echocardiograms 
in subclinical RHD, the World Heart Federation (WHF) 
developed a set of consensus-based criteria – the 2012 
WHF criteria for echocardiographic diagnosis of RHD (21) 
(Table 1).
The criteria have been widely adopted and have 
resulted in the publication of a wealth of standardised 
data that document a latent RHD disease burden of 
epidemic proportions amongst African school-going 
children (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32). This 
provides an impetus for African countries to endorse 
the recommendations of the Addis Ababa Communique 
and amend health policy accordingly to include routine 
RHD screening. However, the screening experience 
whilst utilising the WHF criteria has also raised sufficient 
concern to limit its implementation in resource-restricted 
areas (33, 34, 35). This is due to various methodological 
and performance-related issues that will require further 
scrutiny and possible amendment should large-scale RHD 
screening be endorsed in the future.
These concerns are broadly summarised and discussed 
as follows:
1.  The state of African health care systems.
2.  The logistical requirements of the WHF criteria.
3.  Simplification of the WHF criteria.
4.  Methodological deficiencies in the WHF criteria.
5.  The natural history of subclinical RHD.
The state of African health care systems
The Addis Ababa Communique identifies the importance 
of decentralising the diagnostic services for RHD to 
district and primary health care hospitals in Africa. This 
involves the training of designated health care workers 
in echocardiography and the provision of adequate 
Table 1 
Echocardiographic criteria for RHD in individuals ≤20 years
For definite RHD (either A, B, C or D)
A: Pathological MR and ≥2 morphological features of RHD 
of the MV
B: MS (mean gradient ≥4 mmHg)
C: Pathological AR and ≥2 morphological features of RHD 
of the AV
D: Borderline disease of both the MV and AV
For borderline RHD (either A, B or C)
A: ≥2 morphological features of RHD of the MV without 
pathological MR or MS
B: Pathological MR
C: Pathological AR
Echocardiographic criteria for pathological regurgitation
Doppler echocardiographic criteria for MR (all four  
must be met)
1.  Seen in two views
2.  In at least one view, jet length ≥2 cm
3.  Velocity ≥3 m/s for one complete envelope
4.  Pansystolic jet in at least one envelope
Doppler echocardiographic criteria for AR (all four must 
be met)
1.  Seen in two views
2.  In at least one view, jet length ≥1 cm
3.  Velocity ≥3 m/s for one complete envelope
4.  Pan-diastolic jet in at least one envelope
Echocardiographic criteria for morphological features of RHD
Features in the MV
 • AMVL thickening ≥3 mm
 • Chordal thickening
 • Restricted leaflet motion
 • Excessive leaflet tip motion during systole
Features in the AV
 • Irregular or focal thickening
 • Coaptation defect
 • Restricted leaflet motion
 • Prolapse
AMVL, anterior mitral valve leaflet; AR, aortic regurgitation; AV, aortic 
valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; 
RHD, rheumatic heart disease.
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ultrasound equipment, technical support and basic 
infrastructural requirements to create a sustainable 
service. However, this poses a massive challenge to 
African countries whose overextended health systems are 
limited by budgetary constraints, excessive disease burden 
and dire shortages of skilled staff (36). Furthermore, an 
important limitation that has been described in African 
RHD literature is the frequency of enrolled participants 
who are subsequently ‘lost to follow-up’. This is attributed 
to various factors, which include a high ‘drop-out rate’ 
amongst school children, a ‘migratory culture’ amongst 
certain communities and poor access to mobile phone 
technology (23, 32, 37). Although these difficulties are 
inherent in any study, they are nonetheless obstacles that 
can impact significantly on the success of a programme.
The minutiae detailing presents health care constraints 
and the reform that is required to successfully implement 
effective RHD screening in African countries lies outside 
the scope of this article. These challenges however must 
be borne in mind as they arguably represent the most 
significant obstacle to the institution of a successful 
screening programme in resource-poor settings.
The logistical requirements of the WHF criteria
To provide an evidence-based guideline for the detection 
of RHD, a screened case with either mitral or aortic valve 
regurgitation is evaluated according to specific Doppler-
based measurements (Table  1). These include various 
spectral Doppler parameters that effectively limit the ‘gold 
standard’ technology with which to effectively screen for 
RHD to echocardiographic machines that are equipped 
with this functionality.
These units are expensive and are dependent on 
a reliable supply of wired electricity making them 
unattractive options for use in a resource-limited setting 
(29, 31).
The advent of the hand-held echocardiographic 
device has heralded an attractive solution for large-scale 
screening programmes as they are portable, battery 
powered and marketed at a fraction of the cost of the 
conventional machines. The advantages of portability and 
cost of the units are however somewhat offset by various 
technological issues that require further elucidation.
Firstly, the most notable disadvantage of the current 
hand-held devices is the absence of spectral Doppler 
functionality, which as previously indicated is mandatory 
for the successful utilisation of the current criteria. 
Secondly, the unit scans with obligatory tissue harmonic 
imaging (THI) that could explain the observation made by 
Beaton and coworkers (29) of thicker cardiac structures and 
increased false-positive diagnoses of chordal thickening 
and leaflet restriction in their studied cohort. In addition, 
the WHF guideline recommends that anterior mitral valve 
leaflet thickness measurements obtained using THI should 
be cautiously interpreted and a thickness of up to 4 mm 
should be considered normal in individuals ≤20 years of 
age (21). Thirdly, the potential discrepancies in the leaflet 
assessment are further exacerbated by a basic ‘point-of-
care’ measurement tool that is limited to one millimetre 
increments and has been recognised to overestimate leaflet 
thickness (29). Lastly, the units require regular recharging 
due to a limited battery lifespan and overheat during 
prolonged scanning with the added risk of a reduction in 
scanning frame rate. (30, 31, 38).
Simplification of the WHF criteria – a solution for 
large-scale screening?
Marijon and coworkers (1) describe a two-step screening 
process whereby health care workers (nurses/technicians) 
identify potential RHD cases using a hand-held device 
with a basic on-site screening protocol. Positive cases 
are then referred to a medical centre equipped with a 
comprehensive echocardiographic machine for a second 
confirmatory scan.
Recent RHD research has thus focused on simplifying 
the current WHF criteria to enable its incorporation into 
hand-held screening protocols (25, 29, 30, 31, 39, 40). 
The use of a single mitral regurgitation (MR) jet length 
measurement to denote RHD has been put forward (41) 
and remains an attractive option, but may contrive to 
cause undesirable consequences.
Firstly, validation of the ‘focused’ protocol becomes 
problematic as the same parameter remains at the crux 
of the comprehensive WHF functional assessment and 
risks confirmation bias (42). Secondly, it risks missing true 
rheumatic disease cases with either isolated morphological 
features or a functional assessment measurement just 
below the cut-off value (reducing sensitivity of the criteria) 
(7). Thirdly, an additional case-load of alternative causes 
of ‘pathological MR’ could be included in this subset 
(reducing specificity), which may overburden the tertiary 
referral-care services and swamp the ‘already stretched 
paediatric cardiology services’ (7). Fourthly, it overlooks 
the finding of Marijon and coworkers who noted that 
their ‘combined criteria’ (requiring features of chronic 
morphological RHD and any degree of regurgitation) led to 
a markedly improved detection rate of RHD as compared 
to a functional Doppler assessment alone (43). Lastly, the 
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impact of a false-positive result on an individual patient 
level cannot be discounted and would undoubtedly result 
in unnecessary anxiety and the inappropriate prescription 
of long-term secondary prophylaxis (7, 44).
Methodological deficiencies in the WHF criteria
Lack of a RHD-specific scanning protocol A 
challenging aspect of RHD screening remains the 
identification of subtle structural changes that are 
recognised to only affect specific leaflet segments. The 
WHF guideline recognises this and cautions that some 
children with pathology will be missed if only ‘standard, 
adult-style echocardiographic views are assessed’ (21).
The current guideline however, does not define a 
standardised screening protocol that will successfully 
identify subtle RHD pathology. The validation and 
subsequent introduction of a tailored screening protocol 
for RHD identification could improve the overall standard 
of screening and potentially reduce the amount of missed 
RHD cases.
The Doppler criteria and alternative causes of 
pathological MR The Doppler criteria stem from early 
Doppler-work that identified its potential to effectively 
differentiate between physiological and pathological 
regurgitant jets (45, 46, 47, 48). This body of research was 
incorporated into echocardiographic criteria used to 
identify subclinical ARF carditis (49, 50) and later RHD 
(51). The Doppler criteria were amalgamated into the 
current 2012 WHF criteria largely based on data suggesting 
that pathological MR was more likely to be observed in 
children in high-risk RHD areas than low-risk RHD areas 
(52) (Table 1).
The criteria however have been identified as a 
shortcoming of the current WHF guideline for two 
principal reasons. Firstly, they comprise a set of somewhat 
arbitrary and redundant parameters, which include 
a non-physiological regurgitant jet velocity cut-off 
(42, 53), a requirement to identify the jet in two views 
(testing only the screener’s ability) (42), the requirement 
of a pansystolic/pan-diastolic jet, which provides no 
additional information regarding the mechanism of 
regurgitation (42) and a jet-length measurement that is 
subject to interobserver variability and whose specificity 
in identifying disease progression has been questioned 
(25). Use of the current Doppler criteria could risk labelling 
screened cases of arguably true RHD (with specific 
morphological features of RHD) as ‘borderline RHD’ 
because they are deficient in any one of the measured 
Doppler parameters (Figs 1, 2 and Videos 1, 2).
Secondly, the incorporation of a ‘borderline RHD’ 
category to improve the sensitivity of the WHF criteria has 
illuminated the Doppler criteria’s lack of specificity. This is 
Figure 1
Still image taken from a screening 2D echocardiogram in a parasternal 
long axis view. There are morphological features of RHD of the mitral 
valve (diastolic restriction of both leaflets with thickening of the leaflet 
tips. See also Video 1.
Figure 2
Still image of corresponding case with colour Doppler interrogation of 
the mitral valve. There is pixel mitral regurgitation during ventricular 
systole. The regurgitant jet measured <2 cm and therefore case 
designated as ‘borderline RHD’. See also Video 2.
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exemplified by the finding of ‘pathological MR’ that was 
attributable to congenital mitral valve (MV) variants in 
screened cases from both high- and low-risk populations 
(24, 52, 53, 54, 55) (Figs 3, 4, 5, 6 and Videos 3, 4, 5).
The WHF guideline made provision for this 
contingency by adding a pre-requisite that ‘congenital, 
acquired and degenerative heart disease of the MV and AV’ 
are excluded before presuming rheumatic origin (21). The 
guideline further adds that ‘congenital cardiac defects are 
easily differentiated from RHD, as they have unique identifying 
features (for example, bicuspid AV or MV cleft)’ (21). Whilst 
this may be true for entities such as the bicuspid AV, MV 
cleft and MV prolapse that have been well described 
in both anatomical pathology and echocardiographic 
literature and have pathognomonic echocardiographic 
features that identify them as such. The premise however 
does not hold true for all cases that are identified as 
‘borderline’ RHD based on an isolated pathological MR 
jet. A subset of these cases has been alluded to in current 
RHD literature as being on the ‘upper limit of physiological 
mitral valve regurgitation’ (56) or screened cases with 
‘minor congenital MV anomalies’ (53). However, the exact 
Figure 3
Still image taken from a screening 2D echocardiogram in a parasternal 
long axis view with mitral valve leaflets at maximal diastolic excursion. 
There are no morphological features of RHD of the mitral valve 
(both leaflets are thin and demonstrate no diastolic restriction). 
See also Video 3.
Figure 4
Still image of corresponding case during ventricular systole with colour 
Doppler interrogation of the mitral valve. The white arrow shows WHF 
pathological mitral regurgitation during ventricular systole. The 
regurgitant jet measured >2 cm and met all additional Doppler criteria. 
The screened case is therefore case designated ‘borderline RHD’. See also 
Video 4.
Figure 5
Still image of corresponding case with continuous-wave Doppler trace 
through the mitral valve. The trace confirms a pansystolic jet with a 
complete envelope and a peak velocity > 3m/s.
Video 1
Screening 2D echocardiogram in a parasternal long axis 
view. There are morphological features of RHD of the 
mitral valve (diastolic restriction of both leaflets with 
thickening of the leaflet tips). View Video 1 at http://
movie-usa.glencoesoftware.com/video/10.1530/ERP-17-
0037/video-1.
Video 2
Colour Doppler interrogation of the mitral valve. There is 
pixel mitral regurgitation during ventricular systole. The 
regurgitant jet measured <2 cm and therefore case 
designated as ‘borderline RHD’. View Video 2 at http://
movie-usa.glencoesoftware.com/video/10.1530/ERP-17-
0037/video-2.
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mechanism of valvular incompetence in these cases has 
not been identified.
An additional cause for concern is the description of 
an entity identified in South African high-risk children 
that may be mistakenly identified as potential RHD. These 
have been described as normal spectrum MVs with WHF 
pathological regurgitation identified through ‘prominent 
posterior leaflet interscallop separations’ (42). Currently, 
it remains unclear as to whether these ‘interscallop 
separations’ are related to similar entities described in 
the literature as posterior MVs with ‘isolated clefts’ (57), 
‘subclefts’ (58), ‘interscallop malcoaptations’ (57) and ‘slits’ 
(59). It is evident that more work is required to investigate 
and describe the aetiology, common echocardiographic 
characteristics and clinical course of non-rheumatic MVs, 
which display WHF pathological MR.
The natural history of subclinical RHD An early 
echocardiographic diagnosis of subclinical RHD has 
particular bearing for screened cases in resource-poor 
African countries. In these communities, the management 
options for individuals with symptomatic severe RHD 
become extremely limited due to constrained 
cardiothoracic/interventional cardiology services (60). 
Individuals identified with subclinical disease in these 
instances would intuitively benefit the most from the 
early institution of an appropriate secondary prophylaxis 
regimen to avert progression to symptomatic disease.
However, the efficacy of secondary prophylaxis 
to prevent further ARF recurrences and progression 
of clinically detectable RHD cannot be automatically 
extrapolated to include screened cases with subclinical 
RHD (56). This is in part related to the paucity of long-
term echocardiographic follow-up studies utilising 
standardised diagnostic and reporting methodology (21). 
Furthermore, the establishment of a randomised control 
trial (RCT) evaluating prophylaxis vs no prophylaxis 
in subclinical RHD is controversial as it is considered 
that withholding prophylaxis to an individual with 
WHF-identified ‘definite RHD’ is unethical (56).
The diagnostic confidence that a ‘borderline RHD’ 
diagnosis conveys however is not as robust. The borderline 
group was introduced to improve the sensitivity of the 
guideline at the expense of the specificity and has resulted 
in the identification of a large, diverse indeterminate 
group of cases with unknown clinical significance. 
Accordingly, the WHF guideline does not advocate that 
patients with ‘borderline RHD’ disease receive penicillin 
prophylaxis. This has become the subject of much debate 
amongst members of the RHD research community with 
the suggestion that the use of screening echocardiography 
in subclinical RHD should for now, be viewed as a research 
tool, pending more definite studies of impact on prognosis 
(7, 33, 52, 53, 54, 55, 61, 62).
Figure 6
Still image of corresponding case in parasternal short axis view. There is a 
prominent interscallop separation of the posterior leaflet. Colour Doppler 
interrogation subsequently demonstrated the interscallop separation to 
be the cause of the incompetence. See also Video 5.
Video 3
Screening 2D echocardiogram in a parasternal long axis 
view with mitral valve leaflets at maximal diastolic 
excursion. There are no morphological features of RHD 
of the mitral valve (both leaflets are thin and 
demonstrate no diastolic restriction). View Video 3 at 
http://movie-usa.glencoesoftware.com/video/10.1530/
ERP-17-0037/video-3.
Video 4
Ventricular systole with colour Doppler interrogation of 
the mitral valve. There is WHF pathological mitral 
regurgitation during ventricular systole. The regurgitant 
jet measured >2 cm and met all additional Doppler 
criteria. View Video 4 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-17-0037/video-4.
Video 5
Inparasternal short axis view. There is a prominent 
interscallop separation of the posterior leaflet. Colour 
Doppler interrogation subsequently demonstrated the 
interscallop separation to be the cause of the 
incompetence. View Video 5 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-17-0037/video-5.
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Five research groups who have followed cohorts of 
screened WHF subclinical RHD cases have subsequently 
published their findings (25, 33, 37, 62, 63) (Fig.  7). 
Despite various limitations, which include small cohorts 
and relatively short-term follow-up, the studies do 
provide a preliminary insight into the natural history of 
WHF subclinical disease and may highlight important 
principles that are deficient in the current guideline.
All five publications identify that the natural history 
of a screened borderline RHD case is not necessarily benign 
(Fig.  7). There is a variable, yet, significant proportion 
of borderline cases that have been demonstrated to 
persist at follow-up and a smaller population displaying 
progression to ‘definite RHD’. Despite the documented 
risk of disease persistence and progression, the hallmark 
of ‘borderline RHD’ was its predilection to revert back to 
normal with so-called ‘disease regression’ demonstrated 
in the majority of these longitudinal studies (Fig.  7). 
Various reasons have been offered to account for these 
findings that include issues with interobserver variability 
(37, 63), the administration of secondary prophylaxis 
(25), the inability of the WHF criteria to classify screened 
individuals >20 years of age into a borderline group (37) 
or even that subclinical RHD represents a disease process 
that can resolve back to normal in a large majority of 
cases (37).
The notion of disease regression and improvement of 
‘pathological’ lesions whether they be morphological or 
functional raises some important issues that beg further 
investigation. All else being equal, one would expect 
that chronic RHD morphological abnormalities such as 
thickening and restriction of the valvular and subvalvular 
apparatus will persist and are unlikely to improve over 
time. The identification of these morphological features 
could therefore represent the most specific predictor for 
true RHD (25, 62, 63).
If this hypothesis is demonstrated to be true, could 
the finding of subclinical RHD disease regression be a 
false representation of the natural history of true RHD 
and could the current WHF screening methodology be 
responsible for perpetuating this anomaly?
An alternative RHD screening methodology
A recent commentary of the WHF criteria (42) has 
proposed an alternative RHD screening methodology that 
deviates from the precepts incorporated in the current 
guideline.
The commentary argues that the pattern of ‘diastolic 
leaflet restriction’ remains a principal finding in RHD 
and advocates that a comprehensive leaflet assessment 
be assimilated into a screening protocol to identify 
subtle focal RHD involvement. It further recognises that 
the current morphological and functional assessment 
comprises inherent technical and methodological pitfalls 
that necessitate further scrutiny and potential amendment 
as they may impede on the guideline’s performance. The 
most notable amendment proposed in this manuscript 
is that the presence of regurgitation (of any degree) in 
a screened valve should prompt an active search for the 
mechanism of dysfunction. This so-called ‘mechanistic 
evaluation’ would be incorporated in lieu of the current 
Doppler assessment and could potentially discriminate 
between subtle cases of true RHD and the extraneous 
mimics of RHD identified in the ‘borderline RHD’ category. 
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Figure 7
A comparison of the natural history of borderline 
rheumatic heart disease in five studies with 
increasing number of studied participants 
(m, mean duration of follow-up in months; 
n, sample size of borderline cases). *Rémond and 
coworkers’ publication only presented persistence 
and progression data from their cohort (62). The 
presented regression data are thus inferred 
considering the total number of borderline cases 
that were followed up.
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It must be noted that the skill level required to complete 
such an evaluation will undoubtedly limit its applicability 
in ‘on-site screening’ and will realistically (3) only be 
incorporated for use by experienced echocardiographers 
during the confirmatory scan.
Nonetheless, the mechanistic evaluation, although 
untested in RHD identification may prove to be of merit 
as it echoes the general principles expounded in current 
echocardiographic recommendations for the evaluation 
of native valvular regurgitation (64).
Conclusion
The establishment of the WHF criteria for the 
echocardiographic diagnosis of RHD represents a significant 
endeavour to combat the scourge of RHD across the globe. 
The guideline has undoubtedly standardised the process 
of disease identification, kindled further RHD research 
ventures across the African continent and deepened our 
understanding of subclinical disease progression. Above 
all, the criteria have highlighted the excessive burden 
of disease across the continent and with it prompted 
African leaders to implement large-scale health policy 
reform. However, various logistical and methodological 
shortcomings have prevented its endorsement in large-
scale screening programmes and cast doubt on the findings 
of long-term cohort studies of subclinical disease. At the 
heart of some of these shortcomings lies the difficulty 
of accurate RHD case detection using echocardiography. 
Our pursuit to improve this accuracy may necessitate a 
paradigm shift in the echocardiographic approach we use.
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